NCT00953745View on ClinicalTrials.gov

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

NACompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

December 31, 2012

Conditions
Major Depressive Disorder
Interventions
DRUG

Escitalopram

All subjects will begin on escitalopram and placebo for 8 weeks

DRUG

Aripiprazole

Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.

DRUG

Placebo Capsule

All subjects will begin on escitalopram and placebo capsule for 8 weeks.

DRUG

Placebo Tablet

After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.

Trial Locations (1)

63110

Washington University in St. Louis, School of Medicine, St Louis

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Washington University School of Medicine

OTHER